New strategies for managing drug spend: RA, Cancer, Hep C March 04, 2017 The proliferation of specialty drugs has prompted new techniques for keeping costs in tow. Six diseases reap benefits of biomarkers, genetic tests March 02, 2017 By Karen Appold Biomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening. Protocols for High-Risk Pregnancies: Autoimmune Disease February 01, 2017 By Judith M. Orvos ELS In this protocol, Dr Lockwood reviews the pathophysiology, diagnosis, and management of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA). Will new autoimmune drugs address cost concerns? December 27, 2016 By Erin Bastick PharmD Find out what’s in the drug pipeline for autoimmune disease. Integrating pharmacy benefit, medical benefit cuts costs November 29, 2016 By Tracey Walker Here’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs. Rheumatoid arthritis: Partnering for optimal care October 10, 2016 The goal of this activity is to educate pharmacists and technicians in how best to assist patients in the use of medications used to treat rheumatoid arthritis. Will docs prescribe the new RA biosimilars? October 07, 2016 By Christine Blank While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs. Nearly half of BCBS members discontinue this RA drug after 1 year October 06, 2016 By Tracey Walker Analysis from Prime shows that improvements in persistency, adherence is key in RA treatments. Health execs must brace for autoimmune drug changes October 05, 2016 By Tracey Walker A comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information. Five specialty pharmaceutical trends to watch October 05, 2016 By Aubrey Westgate Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.